Gaël Coadou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gaël Coadou has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Launay
Institut de Chimie Organique et Analytique (ICOA), CNRS FR 2708 - UMR 7311, Université d'Orléans, 45067, Orléans, France
1 shared publication- Alina Ghinet
Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, UMR 1167 – RID-AGE – Risk Factors and Molecular Determinants of Aging-Related Diseases, F-59000 Lille, France
1 shared publication Anne-Sophie Voisin-Chiret
Normandie Univ, UNICAEN, CERMN, Caen, 14000, France
1 shared publicationAntoine Morvan
Univ. Lille, Inserm, Institut Pasteur de Lille, U1167 - Risk factors and molecular determinants of aging-related diseases, F-59000 Lille, France
1 shared publication- Arnaud Tatibouët
GlycoBio&Chemistry Team, ICOA, UMR 7311, Université D’Orléans et CNRS , BP 6759, Orléans F-45067
1 shared publication - Asma Bourafai-Aziez
Evear Extraction Coutures France
1 shared publication
Latest Publications
- Open Access
- 29 October 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1382, 344837
LIM kinase/inhibitor binding study in cell lysates using microscale thermophoresis in the red spectrum
- 29 October 2025
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1382, 344837
Open AccessLIM kinase/inhibitor binding study in cell lysates using microscale thermophoresis in the red spectrum
- 13 May 2022
- Published by Elsevier in Journal of Chromatography A
- Vol. 1674, 463115
Supercritical fluid chromatography for separation of chiral planar metallocenes
- 13 May 2022
- Published by Elsevier in Journal of Chromatography A
- Vol. 1674, 463115
Supercritical fluid chromatography for separation of chiral planar metallocenes
- Open Access
- 1 December 2021
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 15, 5035-5059
Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
Introduction: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1. Results: A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the anti-apoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the Deferasirox:Mcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234. Conclusion: Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor.
- 1 December 2021
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 15, 5035-5059
Open AccessDrug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1
Introduction: With the aim of repositioning commercially available drugs for the inhibition of the anti-apoptotic myeloid cell leukemia protein, Mcl-1, implied in various cancers, five molecules, highlighted from a published theoretical screening, were selected to experimentally validate their affinity toward Mcl-1. Results: A detailed NMR study revealed that only two of the five tested drugs, Torsemide and Deferasirox, interacted with Mcl-1. NMR data analysis allowed the complete characterization of the binding mode of both drugs to Mcl-1, including the estimation of their affinity for Mcl-1. Biological assays evidenced that the biological activity of Torsemide was lower as compared to the Deferasirox, which was able to efficiently and selectively inhibit the anti-apoptotic activity of Mcl-1. Finally, docking and molecular dynamics led to a 3D model for the Deferasirox:Mcl-1 complex and revealed the positioning of the drug in the Mcl-1 P2/P3 pockets as well as almost all synthetic Mcl-1 inhibitors. Interestingly, contrary to known synthetic Mcl-1 inhibitors which interact through Arg263, Deferasirox, establishes a salt bridge with Lys234. Conclusion: Deferasirox could be a potential candidate for drug repositioning as Mcl-1 inhibitor.
- 1 December 2019
- Published by Elsevier in Molecular Catalysis
- Vol. 479, 81-87
S-glycosyltransferase UGT74B1 can glycosylate both S- and O-acceptors: mechanistic insights through substrate specificity
- 1 December 2019
- Published by Elsevier in Molecular Catalysis
- Vol. 479, 81-87
S-glycosyltransferase UGT74B1 can glycosylate both S- and O-acceptors: mechanistic insights through substrate specificity